Clinical Trials Browser

Resectable HER2-positive Breast Cancer

Non-Muscle Invasive Bladder Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Sarcoma, Osteosarcoma

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

Breast Neoplasms

Stomach Neoplasms

Patients With Advanced or Metastatic Solid Tumors

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Stomach Neoplasms

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Adenocarcinoma

Breast Neoplasms

Clinical Trials

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

MK-5890-003

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

APHINITY

MK-3475-522

KEYNOTE-756

FAST

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

TROIKA

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

TP-II

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

ACCRUE

ASCERTAIN

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

INDUCT

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

MATRIX EG

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

ELATE

A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors

To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer

CHERLOB

Phase I Combination w/ Epirubicin

RILOMET-1

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer